Begin main content

Call for Feedback: Dual Antiplatelet Therapy Following Percutaneous Coronary Intervention: Clinical and Economic Impact of Standard Versus Extended Duration

February 20, 2018
A document related to the project entitled on Dual Antiplatelet Therapy Following Percutaneous Coronary Intervention: Clinical and Economic Impact of Standard Versus Extended Duration is now available for feedback from all interested stakeholders. Project Call for Feedback Feedback Due By Dual Antiplatelet Therapy Following Percutaneous Coronary...

New at CADTH — February 2018

February 16, 2018
Read this month’s issue of New at CADTH. Here, you’ll find the latest information on our products and services, corporate news, and news flashes of upcoming events across Canada.

Pharmaceutical Review Program Updates (CDR Update 133 and pCODR Update 63)

February 13, 2018
Today CADTH is pleased to announce operational changes that will enhance our Common Drug Review and pan-Canadian Oncology Drug Review programs. These changes reflect our careful consideration of stakeholder feedback and input from the participating jurisdictions.  For complete details regarding the revised biosimilar review process and applicati...

New Fee Guidance for Applications to CADTH’s Pharmaceutical Review Programs

February 13, 2018
CADTH has implemented a new fee structure that applies to both the Common Drug Review and pan-Canadian Oncology Drug Review programs. The new Guidelines on Application Fees for CADTH Pharmaceutical Reviews  replace the separate application fee guidelines which previously existed for each program. Other important highlights include: a reduced fee...

CADTH Lecture Series – Gene Therapy: A Scientific Renaissance?

February 8, 2018
Matthew Seftel, MD, MPH, FRCP, FRCPC Head, Department of Medical Oncology and Hematology, CancerCare Manitoba Associate Professor, Section of Hematology/Oncology, Department of Internal Medicine, University of Manitoba For diseases caused by inherited or acquired genetic mutations, the ideal remedy is to correct the relevant mutations. Recently,...